Background: Alcohol tolerance and withdrawal-induced effects are criteria for alcohol use disorders listed by the DSM-V. Although tolerance and withdrawal have been studied over many decades, there is still uncertainty regarding mechanistic distinctions that characterize these different forms of ethanol (EtOH)-induced plasticity. Previously, we demonstrated that the suprachiasmatic nucleus (SCN) circadian clock develops both acute and rapid tolerance to EtOH inhibition of glutamate-induced circadian phase shifts. Here, we demonstrate that chronic EtOH tolerance and withdrawal-induced glutamate hypersensitivity occur in vitro and that rapid tolerance, chronic tolerance, and glutamate hypersensitivity have distinct cellular changes.
A LCOHOL USE DISORDERS (AUD) develop after long periods of ethanol (EtOH) consumption. Investigations of the cellular processes associated with AUD are complicated because the effects of EtOH change as one progresses from short-term to long-term drinking. This transition is clinically relevant, however, as it likely contributes to development of AUD (Costin and Miles, 2014; Hagman and Cohn, 2011) . The acute effects of EtOH include inhibition of glutamate signaling and enhancement of GABA signaling (M€ oykkynen and Korpi, 2012; Proctor et al., 2006; Roberto et al., 2004) . Extended EtOH exposure leads to changes in synaptic localization, total expression, and phosphorylation of receptor proteins (Clapp et al., 2010; Roberto et al., 2004; Wu et al., 2010) . Although these effects are seen throughout the brain, the specific changes appear to differ regionally. Further complicating the picture, varying EtOH exposure paradigms have been used to investigate EtOH-induced changes in different brain areas, including the suprachiasmatic nucleus (SCN) (Brager et al., 2010; Lindsay et al., 2014; Prosser and Glass, 2009; Prosser et al., 2008; Rosenwasser et al., 2014; Ruby et al., 2009; Seggio et al., 2009) .
A critical component of the transition from social drinking to EtOH abuse is thought to be a decrease in sensitivity to EtOH-induced effects, termed tolerance. Three major forms of EtOH tolerance have been described that differ based on time after initial exposure: acute tolerance (observed 5 to 15 minutes after drinking), rapid tolerance (observed 8 to 24 hours after drinking), and chronic tolerance (develops after days/weeks of EtOH exposure). For example, acute tolerance is seen with respect to ataxia and motor impairment (Gill and Deitrich, 1998; Ramirez et al., 2011) , rapid tolerance with hypothermic and hypnotic effects (Gilliam, 1989; Silveri and Spear, 1999) , and chronic tolerance with sleep and loss of righting reflex (Daut et al., 2015; Dyr and Taracha, 2012) . Although the mechanisms underlying these different forms of tolerance are still under investigation, many cellular changes have been noted. With tolerance in general, glutamate and c-aminobutyric acid (GABA) systems adapt to increase and decrease their baseline signaling properties, respectively. Acute tolerance has been linked to increased expression of N-methyl-D-aspartate (NMDA) receptor NR2A and NR2B subunits in the hippocampus and cortex (Roh et al., 2011) . Transgenic studies also suggest a role for a1 subunits of GABA receptors in acute tolerance (Werner et al., 2009 ). Finally, changes in expression and phosphorylation of key residues of NMDA and GABA receptor subunits have been demonstrated during chronic tolerance (Kroener et al., 2012; Liang et al., 2007; Lindemeyer et al., 2014; Wang et al., 2011; Wu et al., 2010) . EtOH withdrawal following chronic exposure is typically characterized by insomnia, psychomotor agitation, hallucinations, and delirium tremens (Schuckit, 2014) . At the cellular level, withdrawal is accompanied by changes in both glutamate and GABA signaling (Carlson et al., 2016; Clapp et al., 2010) .
In summary, the cellular mechanisms associated with acute, rapid, and chronic EtOH tolerance and EtOH withdrawal appear to differ (Clapp et al., 2010; Lindsay et al., 2014; Radcliffe et al., 2006; Roberto et al., 2006; Tran et al., 2015) . However, rarely have the cellular mechanisms underlying these different forms of EtOH-induced plasticity been assessed in a single study. Thus, our goal was to assess functional and protein changes in the SCN across multiple forms of EtOH tolerance and EtOH withdrawal.
We use the SCN circadian clock as a model system to investigate EtOH. The SCN circadian clock is the primary endogenous oscillator regulating daily rhythms in behavior and physiology in mammals. External cues such as light phase-shift the circadian clock to maintain proper synchrony with the environment. AUD is often accompanied by disrupted circadian rhythms, including sleep, and these disruptions may contribute to drinking relapse (Brower, 2003; Gillin et al., 1994) .
Light-and glutamate-induced phase resetting in the SCN clock requires NMDA receptor activation (Ding et al., 1997; Mintz et al., 1999; Wang et al., 2008) . Numerous studies have shown that EtOH disrupts the ability of the SCN clock to respond to synchronizing cues such as light. For example, EtOH administration alters the circadian clock free-running period in vivo and inhibits photic phase resetting in rodents acutely in vivo Ruby et al., 2009) , acutely in vitro Prosser et al., 2008) , and chronically in vivo (Brager et al., 2010; Rosenwasser et al., 2005; Ruby et al., 2009; Seggio et al., 2009) . Because EtOH is known to disrupt NMDA receptor function across a variety of exposure paradigms, we chose NMDA receptors as our primary focus for assessing EtOH-induced cellular changes. Previously, we showed that acute tolerance and rapid tolerance to EtOH occur in the SCN in mice (Lindsay et al., 2014; Prosser and Glass, 2009 ). Here, we expand upon these studies, showing that chronic tolerance and withdrawal-induced glutamate hypersensitivity also develop in the SCN in vitro, and these EtOH-induced changes are each accompanied by distinct changes in specific parameters of NMDA receptor expression and closely associated signaling mechanisms.
MATERIALS AND METHODS

Mice
Adult (~8-week-old) C57BL/6 adult male mice were obtained from Envigo (Indianapolis, IN). Mice were individually housed in polycarbonate cages under a 12:12 light/dark cycle, with food and water available ad libitum unless otherwise noted. The experiments followed the National Institution of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the University of Tennessee Knoxville Institutional Animal Care and Use Committee. In all experiments, mice were allowed access to either water or 15% EtOH from drip-resistant sipping tubes (Med Associates, Inc., St. Albans, VT).
Brain Slice Preparation and Drinking Schedules
The different drinking paradigms used in this study are illustrated in Fig. 1 . The rapid tolerance drinking paradigm was performed as described in Lindsay and colleagues (2014) . Briefly, mice had their water bottle replaced with one containing a 15% EtOH/water solution for a single 12-hour lights-off period. At lights on following EtOH access, the volume of EtOH consumed and the weight of the mouse were recorded. Afterward, 500 lm coronal brain slices containing the SCN were prepared for electrophysiological recording or for Western blot assays. Brain slices were maintained at 37°C in an interface style brain slice chamber and perfused with Earle's balanced salt solution (EBSS), pH 7.4, supplemented with 95% O 2 /5% CO 2 , sodium bicarbonate, glucose, and gentamicin.
We used a 4 h/d drinking protocol to investigate chronic tolerance. This involved exchanging the water bottles with ones containing a 15% EtOH/water solution beginning 1 hour prior to lights off and continuing through 3 hours after lights off, for a total of 4 hours. EtOH and water consumption and body weight of each mouse were measured daily. The 4-hour EtOH access protocol continued for 10 to 21 days depending on the experiment. At lights on following the last day of drinking, coronal brain slices containing the SCN were prepared and maintained as described above. We used this drinking protocol because it generated EtOH drinking patterns that were very consistent across different mice and across multiple days within individual mice.
For EtOH withdrawal, mice underwent the chronic drinking protocol for up to 21 days followed by 2 to 6 days with no EtOH access (food and water available ad libitum). At lights on following the withdrawal period, coronal brain slices were prepared and maintained as described above.
Drug Treatment
During the first night after brain slice preparation, SCN tissue received bath application of drugs dissolved in EBSS at Zeitgeber time (ZT) 16 (where ZT0 = lights on and ZT12 = lights off in the animal colony). Drug treatments were performed by stopping the perfusion and replacing perfusion media in the chamber with EBSS containing the drug treatment for 10 minutes. Afterward, the solution was removed and the perfusion was resumed. Drug treatments contained a combination of glutamate (Sigma Aldrich, St. Louis, MO) and EtOH (Decon Laboratories, Inc., King of Prussia, PA). SCN tissue used for Western blot assays, which did not receive in vitro drug treatments, were collected at ZT16 and stored at À80°C until protein extraction.
Electrophysiological Recordings
Extracellular single-unit recordings commenced the morning of the second day in vitro. Recordings were performed using glass microelectrodes filled with 5 M NaCl as in previous studies (Lindsay et al., 2014; Prosser and Glass, 2009; Prosser et al., 2008) . Each cell was recorded for 5 minutes, with at least 5 cells recorded per hour over the course of a 10-hour period. Recordings and firing rate analysis were performed using DataWave software (Loveland, CO). Only cells with a signal-to-noise ratio of greater than 2:1 were analyzed. The firing rates of individual neurons were combined into 2-hour running averages, and the peak in neuronal activity was assessed visually as the time of symmetrically highest activity calculated to the nearest quarter hour (Prosser, 2003; Prosser and Glass, 2009; Prosser et al., 2008) .
Protein Extraction
SCN tissue samples were thawed, placed in RIPA lysis buffer containing 1 mM Tris pH 8.8, 5 mM sodium deoxycholate, 5 mM sodium dodecyl sulfate, 1% Triton, protease inhibitor cocktail (Thermo Scientific, Waltham, MA), and phosphatase inhibitor cocktail (Thermo Scientific), and lysed using 15-second sonication pulses. The supernatant was separated from the pellet using centrifugation at 14,0009g at 4°C. Protein concentrations were determined using a Bradford assay. The supernatant was then loaded into a 7% polyacrylamide gel, and electrophoresis was performed. Proteins were transferred to a polyvinylidene fluoride (PVDF) FL immobilon membrane (EMD Millipore, Billerica, MA) using the Transblot turbo system (Bio-Rad Laboratories, Hercules, CA).
Western Blot Assays
Following protein extraction, Western blots were performed as reported previously (Lindsay et al., 2014) . Briefly, PVDF membranes were blocked with 5% bovine serum albumin in Tris-buffered saline with 20% Tween 20 and then incubated with primary antibodies for 2 hours at room temperature or overnight at 4°C. Primary antibodies used were as follows: a-phospho-Y1472 (1:1,000; EMD Millipore), a-phospho-S1480 (1:1,000; AbCam, Cambridge, UK), a-NR2B (1:1,000; EMD Millipore), a-NR1 (1:1,000; AbCam), a-NR2A (1:1,000, EMD Millipore), a-PSD-95 (1:2,000; EMD Millipore), a-brain-derived neurotrophic factor (a-BDNF; detects both mature [mBDNF] and pro-BDNF [proBDNF]; 1:200; Santa Cruz Biotechnology, Dallas, TX), a-TrkB (detects both full-length and truncated TrkB; 1:200; Santa Cruz), a-phospho-tropomyosin receptor kinase A Y680 (binds correspondingly to Y706 of TrkB; 1:200; Santa Cruz), and a-actin HRP conjugate (Santa Cruz). After rinsing, blots were exposed to secondary antibodies of donkey a-Rabbit (Li-COR, Lincoln, NE) or donkey a-Goat (Li-COR) conjugated to infrared dye (Li-COR). Blots were allowed to incubate for an hour with secondary antibodies. Protein bands were detected using the Imagestudio program (Li-COR). When assessing the ratio of NR2B to NR2A protein expression, the same blot was stripped and re-probed for each protein so that comparisons between relative levels of NR2B and NR2A were made within each blot.
Statistical Methods
All statistical analyses were performed using SigmaPlot (San Jose, CA). Individual mice were considered experimental units for electrophysiological recordings. Tissue from a single mouse (or Fig. 1 . Experimental protocols. (A) For rapid tolerance protocol, mice were allowed overnight access to 15% ethanol (EtOH) on Day 1. At lights on of Day 2, mice were sacrificed and suprachiasmatic nucleus (SCN) brain slices were prepared. At Zeitgeber time (ZT) 16, brain slices were collected and flash frozen for Western blot assays. (B) Chronic tolerance and EtOH withdrawal protocols. For chronic tolerance protocol, mice were allowed 4-hour access to 15% EtOH starting 1 hour prior to lights out and ending 3 hours after lights out for up to 21 days. At lights on of the last day, mice were sacrificed and SCN brain slices were prepared. At ZT16, brain slices received bath-applied drug treatment or were collected and flash frozen for Western blot assays. For drug treatments, the treatment was removed after 10 minutes, and slices were left undisturbed until the next day. The following electrophysiological recordings of SCN neuronal activity were conducted. For the EtOH withdrawal protocol, mice are allowed 4-hour access to 15% EtOH for up to 21 days. Following this, mice were allowed access only to water for 2 to 6 days. At lights on of the final day of EtOH withdrawal, mice were sacrificed and SCN brain slices were prepared. SCN tissue underwent either electrophysiology or Western blotting procedures as described above.
pooled samples when necessary) was the experimental unit for Western blots. Post hoc Holm-Sidak analysis using t-test or analysis of variance (ANOVA) was used for paired comparisons or among multiple comparisons for each experiment, respectively. Significance was considered when p < 0.05.
RESULTS
EtOH Consumption Across Multiple Treatments
Mice allowed to consume EtOH for a single 12-hour lights-off period had an average EtOH consumption of 10.62 AE 0.32 g/kg, n = 112. Mice given 4 hours of daily access to EtOH for 10 days had an average daily EtOH consumption of 3.36 AE 0.23 g/kg/d, n = 93. Mice given 4 hours of daily access to EtOH for 21 days had an average daily EtOH consumption of 2.52 AE 0.24 g/kg/d, n = 29. Because all experiments assessed SCN tissue that had been maintained in vitro for a minimum of 4 hours, we did not measure blood alcohol levels. However, for these 3 groups of mice, based on previous reports of blood alcohol concentration (BAC) levels after comparable amounts of EtOH consumption or EtOH injections, these mice may have experienced peak BACs of 0.11 to 0.16 (Crabbe et al., 2017; Karadayian et al., 2013) .
Chronic Tolerance to EtOH Occurs in the SCN
In brain slices prepared from EtOH-na€ ıve mice, firing rates normally peak around ZT6 ( Fig. 2A ). The mean time of peak in control slices occurred at ZT6.1 AE 0.30 (n = 3), which is consistent with previous research (e.g., Prosser et al., 2008) . To begin assessing the development of EtOH tolerance, we investigated the ability of EtOH to inhibit phase shifts induced by 1 mM glutamate, as we have used in previous studies (Cooper et al., 2017; Prosser et al., 2008) . This concentration of glutamate induces maximal phase shifts of the circadian clock when applied for 10 minutes to SCN-containing brain slices (e.g., Cooper et al., 2017) . As illustrated in data from individual experiments (Fig. 2B ,C) and summarized in Fig. 2G , glutamate (1 mM) applied at ZT16 to SCN slices from EtOH-na€ ıve mice induced a phase delay of~3 hours that was significantly inhibited by coapplication of 20 mM EtOH (1-way ANOVA, F 7 = 17.416 p < 0.001; glutamate treatment in EtOH-na€ ıve mice = À3.34 AE 0.21 hours delay, n = 4, vs. glutamate + 20 mM EtOH = À0.24 AE 0.16 hours delay, n = 3; post hoc analysis: t 7 = 7.377, p < 0.001).
The next set of experiments investigated the effects of glutamate AE EtOH treatments applied to brain slices prepared from mice that had undergone 4 h/d EtOH consumption for 10 days. ANOVA indicated there were significant differences in the time of peak neuronal activity across treatments compared to the time of peak in EtOH-na€ ıve brain slices receiving no treatment (1-way ANOVA, n = 3, F 7 =17.416, p < 0.001). Post hoc analysis determined that brain slices from mice that had undergone 4 h/d EtOH for 10 days exhibited no difference in the time of peak neuronal activity compared to brain slices prepared from EtOH-na€ ıve mice (phase delay after 10-day EtOH with no treatment = À0.67 AE 0.37 hours, n = 3, vs. EtOH-na€ ıve control = À0.0 AE 0.30 hours, n = 3; post hoc analysis: t 7 = 1.374, p = 0.81; Fig. 2G ). Applying 1 mM glutamate alone at ZT16 to brain slices from these mice induced a significant phase delay relative to brain slices from EtOH-na€ ıve mice (phase delay after 10-day EtOH 1 mM glutamate = À2.84 AE 0.21 hours, n = 3, vs. EtOH-na€ ıve control = 0.00 AE 0.30 hours, n = 3; post hoc analysis: t 7 = 5.847, p = <0.001; Fig. 2G ), consistent with the effects of glutamate seen in brain slices from EtOH-na€ ıve mice. However, as seen when comparing Fig. 2F to C, co-applying 20 mM EtOH with 1 mM glutamate to brain slices prepared from these mice did not inhibit the glutamate-induced phase shifts (phase delay after 10-day EtOH 1 mM glutamate with 20 mM EtOH = À2.82 AE 0.45 hours, n = 3, vs. EtOH-na€ ıve control; post hoc analysis: t 7 = 5.804, p < 0.001). However, increasing the concentration of EtOH co-applied with 1 mM glutamate to 200 mM completely blocked the glutamateinduced phase shifts in brain slices prepared from the 10-day EtOH drinking mice (phase delay = À0.32 AE 0.30 hours vs. EtOH-na€ ıve control; post hoc analysis: t 7 = 0.653 p = 0.89; Fig. 2G ). Thus, 4 h/d consumption of EtOH for 10 days decreased the sensitivity of in vitro glutamate-induced phase resetting to EtOH inhibition, consistent with the development of chronic tolerance. To more carefully assess the change in EtOH sensitivity that occurs with this drinking paradigm, we tested the ability of an intermediate concentration of EtOH (150 mM) to inhibit glutamate-induced phase shifts. As seen in Fig. 2G , 150 mM EtOH was also unable to inhibit glutamate-induced phase shifts in brain slices prepared from these mice (phase delay after 10-day EtOH with 150 mM EtOH = À1.82 AE 0.58 hours, n = 3, vs. EtOHna€ ıve control; post hoc analysis: t 7 = 3.743, p = 0.023; Fig. 2G ).
Next, we investigated how many days of EtOH drinking are needed to induce chronic tolerance. As shown in Fig. 2H , 20 mM EtOH continued to inhibit glutamate-induced phase shifts in brain slices after mice had undergone up to 7 days of chronic drinking, but not in brain slices from mice that had consumed EtOH for 8 or more days. One-way ANOVA showed a significant effect of days of EtOH consumption (1-way ANOVA: n = 3, F 11 = 8.582, p < 0.001; phase delay after 7 days of 4 h/d EtOH = À0.65 AE 0.25 hours vs. EtOH-na€ ıve control = 0.00 AE 0.30 hours, n = 3, post hoc analysis: t 11 = 1.210, p = 0.89, n = 3; 8 days EtOH -2.48 AE 0.29 hours vs. EtOH-na€ ıve control, post hoc analysis: t 11 = 4.624, p = 0.001; 9 days EtOH -2.78 AE 0.30 hours vs. EtOH-na€ ıve control, post hoc analysis: t 11 = 5.167, p < 0.001; 10 days EtOH -2.32 AE 0.71 hours vs. EtOHna€ ıve control, post hoc analysis: t 11 = 4.314, p = 0.002). Thus, at least 8 days of drinking EtOH is needed to generate chronic tolerance as assessed under these conditions. A 10-minute bath application of 1 mM Glu at ZT16 to SCN tissue from an EtOH-na€ ıve mouse induced a 2-hour phase delay. (C) Co-application of 20 mM EtOH with 1 mM Glu blocked the Glu-induced phase delay in SCN tissue from an EtOH-na€ ıve mouse, indicating that the Glu-induced phase delay was inhibited. (D) In a control experiment with SCN tissue from a mouse given daily 4-hour EtOH access for 10 days, neuronal activity peaked at ZT6, similar to that shown in A. (E) A 10-minute bath application of 1 mM Glu at ZT16 to SCN tissue from an EtOH-exposed mouse induced~a 2.5-hour phase delay, similar to that shown in B. (F) Co-application of 20 mM EtOH and 1 mM Glu did not inhibit the Glu-induced phase shift in SCN slices from a mouse that had undergone the chronic EtOH protocol for 10 days. Horizontal bars: time of lights off in the animal colony; vertical bars: time of drug treatment(s); dotted line: mean time of peak in control experiments. (G) Shown are the mean AE SEM phase shifts induced by Glu and EtOH treatments applied to brain slices of EtOH-na€ ıve mice and mice after 10 days of the chronic EtOH protocol. In SCN slices from EtOH-na€ ıve mice, Glu-induced significant phase delays that were blocked by 20 mM EtOH. In SCN tissue from chronic EtOH mice, Glu induced significant delays that were not blocked by either 20 or 150 mM EtOH, but were blocked by 200 mM EtOH (n = 3 for each treatment). (H) Plotted are the mean (AE SEM) phase shifts induced by 1mM Glu + 20 mM EtOH applied to brain slices prepared from mice given access to 15% EtOH for varying numbers of days. 20 mM EtOH was able to completely inhibit Glu-induced phase shifts after mice had been exposed to 0 to 7 days of chronic EtOH, no longer inhibited Glu-induced phase shifts after mice had been given access to EtOH for 8 or more days. One-way ANOVA indicated a significant effect of treatment, **Post hoc (Holm-Sidak) test indicates p < 0.01 versus control experiments. ***p < 0.001.
Increased Glutamate Sensitivity in the SCN After 2 Days of Withdrawal from EtOH
Next, we investigated the effects of EtOH withdrawal on the SCN circadian clock. In this case, we assessed changes in the sensitivity of the SCN circadian clock to glutamateinduced phase shifts. First, we generated a dose-response curve for glutamate-induced phase delays in brain slices from EtOH-na€ ıve mice (e.g., Cooper et al., 2017) . There was an abrupt shift from no phase-shifting response with 1 lM glutamate to a maximum~3-hour phase delay with 10 lM glutamate (Fig. 3A) . In contrast, 1 lM glutamate applied to SCN brain slices from mice that had undergone EtOH drinking for 21 days followed by 2 days of withdrawal induced significant phase shifts of about 2.5 hours (1-way ANOVA: n = 3, F 9 = 28.642, p < 0.001; withdrawal 1 lM glutamate À2.32 AE 0.36 hours, n = 3, vs. 0 lM EtOH-na€ ıve À0.0 AE 0.30 hours, n = 3, post hoc analysis: t 9 = 5.842, p < 0.001; vs. EtOH-na€ ıve 1 lM glutamate = 0.25 AE 0.6 hours, n = 3, t 9 = 6.473, p < 0.001) (Fig. 3A) . A similar phase shift was induced by 10 lM glutamate applied to SCN tissue under these conditions, indicating that EtOH withdrawal leads to a change in glutamate sensitivity and not a change in the amplitude of the phase-shifting response.
To assess whether this change in glutamate sensitivity was the result of EtOH withdrawal or whether it was due to the prior EtOH consumption, we investigated the phase-shifting Fig. 3 . SCN circadian clock sensitization to glutamate phase resetting after EtOH withdrawal. (A) Plotted are the mean (AE SEM) phase delays induced by 0 uM, 1 uM, and 10 uM glutamate in SCN tissue from EtOH-na€ ıve mice (white bars, n = 3), mice given access to EtOH (4 h/d) for 21 days (gray bars, n = 3), and mice given access to EtOH for 21 days followed by 2 days of EtOH withdrawal (orange bars, n = 3). ***Post hoc (Holm-Sidak) test indicates p < 0.001 versus tissue from control EtOH-na€ ıve mice. (B) Plotted are the mean (AE SEM) phase delays induced by 1 lM glutamate treatment applied to SCN tissue from mice that had undergone 2 days of EtOH withdrawal after varying numbers of days of chronic drinking. **Post hoc (Holm-Sidak) test indicates p < 0.01 versus tissue from control EtOH-na€ ıve mice. (C) Plotted are the mean (AE SEM) phase delays induced by 1 lM glutamate treatment applied to SCN tissue from mice that had undergone varying durations of EtOH withdrawal after 21 days of chronic drinking. **Post hoc (Holm-Sidak) test indicates p < 0.001 versus 0 lM glutamate EtOH-na€ ıve control.
effects of glutamate applied to brain slices prepared from mice having undergone 21 days of EtOH consumption without subsequent EtOH withdrawal. As summarized in Fig. 3A , neither 1 lM nor 10 lM glutamate was able to induce phase shifts in these brain slices, while a higher concentration of glutamate (100 lM) was sufficient to induce a phase delay (1-way ANOVA: n = 3, F 9 = 28.642, p < 0.001; 1 lM glutamate 21 days 4 h/d EtOH-exposed mice = 0.18 AE 0.08 hours, n = 3, vs. 0 lM EtOH-na€ ıve, post hoc analysis: t 9 = 0.462, p = 1.00; 10 lM glutamate 21 days 4 h/d EtOH-exposed mice = 0.017 AE 0.08 hours, n = 3, vs. 0 lM EtOH-na€ ıve, post hoc analysis: t 9 = 0.042, p = 1.00; 100 lM glutamate 21 days 4 h/d EtOH = À3.40 AE 0.14 hours vs. 0 lM EtOH-na€ ıve, post hoc analysis: t 9 = 8.574, p < 0.001). Thus, immediately prior to EtOH withdrawal, the SCN clock appears to be slightly less sensitive to glutamateinduced phase shifts, and glutamate hypersensitivity develops during the period of EtOH withdrawal.
To clarify the duration of EtOH consumption needed to generate the withdrawal-associated glutamate hypersensitivity, we varied the number of days of EtOH consumption prior to the 2 days of withdrawal. As summarized in Fig. 3B , withdrawal-induced glutamate hypersensitivity was seen after 17 or 21 days of chronic EtOH, but not after 10 or 14 days (1-way ANOVA: n = 3, F = 8.397, p = 0.003; 1 lM glutamate 17-day 4 h/d EtOH with 2-day withdrawal = À2.40 AE 0.50 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 4.057, p = 0.009; 1 lM glutamate 21-day 4 h/d EtOH with 2-day withdrawal = À2.32 AE 0.36 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 3.917, p = 0.009; 1 lM glutamate 14-day 4 h/d = À0.32 AE 0.36 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 0.254, p = 0.81; 1 lM glutamate 10-day 4 h/d EtOH with 2-day withdrawal = À0.32 AE 0.36 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 0.535, p = 0.84). Additionally, we clarified the duration of glutamate hypersensitivity after withdrawal. Withdrawal-induced glutamate hypersensitivity was still apparent after 4 days but not after 6 days of EtOH withdrawal (1-way ANOVA: n = 3, F 4 = 28.967, p < 0.001; 1 lM glutamate 21-day 4 h/d EtOH with 4-day withdrawal = À2.65 AE 0.25 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 7.186, p < 0.001; 1 lM glutamate 21-day 4 h/d EtOH with 6-day withdrawal = 0.017 AE 0.08 hours, n = 3, vs. no EtOH control, post hoc analysis: t 4 = 0.045, p = 0.97; Fig. 3C ).
EtOH-Induced Changes in NR2B:NR2A Ratio, NR2B Phosphorylation, and NMDA Signaling Modulators Previously, we determined that total expression of the NMDA receptor subunit subtype 2B (NR2B) and phosphorylation of the NR2B tyrosine 1472 (Y1472) residue do not change in the SCN during rapid tolerance (Lindsay et al., 2014) . Here, we expanded our investigation of potential changes in NMDA receptors and related proteins in response to varying EtOH exposure and withdrawal paradigms. We performed Western blot assays on SCN tissue from EtOHna€ ıve mice and from mice receiving 1 night (12 hours) of drinking, 10 days or 21 days of 4 h/d drinking, and 21 days of drinking followed by 2 days of withdrawal. As seen in Fig. 4 , no significant changes were observed with respect to total NR2A or NR2B expression in SCN tissue across the 5 conditions (1-way ANOVA NR2A: n = 6, F 4 = 2.115, p = 0.100; 1-way ANOVA NR2B: n = 7 to 11, F 4 = 1.945, p = 0.119). However, the ratio of NR2B:NR2A expression was significantly higher after 21 days of drinking and it remained higher after 2 days of withdrawal when compared to SCN tissue from na€ ıve mice (1-way ANOVA: n = 6, F 4 = 3.987, p = 0.012; 21 days: 3.67 AE 0.84, n = 6, post hoc analysis: t 4 = 3.504, p = 0.017; withdrawal = 3.45 AE 0.57, n = 6, post hoc analysis: t 4 = 3.232, p = 0.030; Fig. 4C ). We also assessed total expression of the NMDA NR1 subunit; however, no changes were observed (1-way ANOVA: n = 4, F 4 = 0.552, p = 0.70; 1 AE 0.00 control, 1.21 AE 0.17 overnight, 1.09 AE 0.15 10 days, 1.34 AE 0.29 21 days, 1.36 AE 0.28 withdrawal; data not shown).
Next, we investigated changes in NR2B subunit phosphorylation. Relative to EtOH-na€ ıve SCN tissue and SCN tissue after overnight EtOH consumption, we found a significant increase in NR2B Y1472 phosphorylation in SCN tissue from mice with 21 days of chronic drinking followed by 2 days of withdrawal, but no significant changes in other groups (1-way ANOVA: n = 3 to 8, F 4 = 3.507, p = 0.018; withdrawal = 4.24 AE 1.23, n = 8, vs. control, post hoc analysis: t 4 = 3.23, p = 0.030; vs. overnight 1.02 AE 0.33, n = 8; post hoc analysis: t 4 = 3.214, p = 0.028; Fig. 5A ). We also assessed the amount of NR2B serine 1480 (S1480) phosphorylation across these same experimental conditions; however, no significant changes were noted (1-way ANOVA: n = 4, F 4 = 0.570, p = 0.69; 1 AE 0.00 control, 1.56 AE 0.39 overnight, 1.07 AE 0.23 10 days, 1.14 AE 0.38 21 days, 1.03 AE 0.33 withdrawal; F 4 = 0.570; data not shown).
Phosphorylation of NMDA receptors has been linked to activation of TrkB receptors. Specifically, binding of mBDNF to TrkB receptors induces autophosphorylation, which leads to increased NR2B Y1472 phosphorylation (Mizuno et al., 2003) . Therefore, to investigate potential upstream mechanisms leading to changes in phosphorylation of NR2B Y1472 in the SCN during tolerance and withdrawal, we investigated changes in proBDNF and mBDNF expression, truncated and full-length TrkB expression, and TrkB phosphorylation in SCN tissue. We found a significant increase in mBDNF total expression during withdrawal compared to tissue from EtOH-na€ ıve controls (1-way ANOVA: n = 6, F 4 = 3.037, p = 0.036; withdrawal = 2.07 AE 0.34, n = 6, post hoc analysis: t 4 = 3.104, p = 0.046; Fig. 5C ). Furthermore, an increase in phospho-TrkB at Tyr 706 occurred during withdrawal compared to all other conditions (1-way ANOVA: n = 4, F 4 = 4.286, p = 0.011; withdrawal = 2.55 AE 0.50, n = 4; vs. control post hoc analysis: t 4 = 3.401, p = 0.039; vs. overnight 1.13 AE 0.168, post hoc analysis: t 4 = 3.114, p = 0.049; vs. 10-day 1.04 AE 0.393, post hoc analysis: t 4 = 3.312, p = 0.042; vs. 21-day 1.08 AE 0.29, post hoc analysis: t 4 = 3.231, p = 0.044; Fig. 5D ). No significant changes were noted for expression of proBDNF (1-way ANOVA: n = 6, F 4 = 0.185, p = 0.94; 1 AE 0.00 control, 1.04 AE 0.16 overnight, 1.14 AE 0.16 10 days, 1.10 AE 0.17 21 days, 1.03 AE 0.10 withdrawal; data not shown), truncated TrkB (1-way ANOVA: n = 4, F 4 = 0.211, p = 0.93; 1 AE 0.00 control, 0.95 AE 0.07 overnight, 0.80 AE 0.24 10 days, 0.84 AE 0.24 21 days, 0.95 AE 0.22 withdrawal; data not shown), or full-length TrkB (1-way ANOVA: n = 4, F 4 = 0.640, p = 0.64; 1 AE 0.00 control, 0.91 AE 0.14 overnight, 1.40 AE 0.45 10 days, 1.01 AE 0.28 21 days, 1.34 AE 0.29 withdrawal; data not shown).
Last, with respect to assessing changes in protein expression, we investigated 2 additional proteins whose expression has been linked to changes in glutamate signaling: the postsynaptic density scaffolding protein, PSD-95, and the tyrosine kinase, Fyn (Prybylowski et al., 2005; Roche et al., 2001 ). However, we found no significant differences in either PSD-95 (1-way ANOVA: n = 7, F 4 = 1.398, p = 0.26; 1 AE 0.00 control, 1.49 AE 0.27 overnight, 1.99 AE 0.44 10 days, 1.01 AE 0.28 21 days, 1.34 AE 0.29 withdrawal; data not shown) or Fyn (1-way ANOVA: n = 6, F 4 = 1.432, p = 0.25; 1 AE 0.00 control, 1.08 AE 0.10 overnight, 0.99 AE 0.13 10 days, 1.56 AE 0.24 21 days, 1.88 AE 0.46 withdrawal; data not shown) in the SCN across all experimental conditions. Fig. 4 . Protein expression of NMDA NR2B and NR2A subunits in the SCN after rapid, chronic 10 days, chronic 21 days, and EtOH withdrawal procedures. (A) Above, plotted are the mean band densities (AE SEM) for NR2A normalized to control tissue and relative to actin (n = 7 for all conditions). Below are representative images for NR2A (170 kDa) and actin (42 kDa) bands across all treatments. (B) Above, plotted are the mean band densities (AE SEM) for NR2B normalized to control tissue relative to actin (n = 7 for chronic 21 days group; n = 11 for all other groups). Below are representative images for NR2B (180 kDa) and actin bands across all treatments, respectively. (C) Plotted are the mean ratios of band densities for NR2B to NR2A normalized to control tissue and relative to actin (n = 7 for all conditions). The same blot was stripped and re-probed for either NR2B or NR2A, so comparisons of NR2B:NR2A ratios were made within each experimental replicate. *Post hoc (Holm-Sidak) test indicates p < 0.05 versus control experiments.
DISCUSSION
Time Course of Chronic Tolerance and Withdrawal
Previously, we demonstrated the SCN develops rapid tolerance after mice are given access to EtOH for a single night, and this tolerance is characterized by a decrease in EtOH inhibition of photic (in vivo) and glutamate-induced (in vitro) circadian clock phase resetting (Lindsay et al., 2014) . Here, we extend these findings to show that the SCN also develops chronic tolerance to EtOH and withdrawal- Fig. 5 . Protein expression for phosphorylated and total NR2B, mBDNF, and phosphorylated TrkB in the SCN after rapid, chronic 10 days, chronic 21 days, and EtOH withdrawal procedures. (A) Plotted are mean band densities (AE SEM) for phosphorylation of the Y1472 residue of NR2B normalized to control tissue and relative to actin across different conditions (n = 3 for chronic 21 days, n = 8 for other conditions). Below are representative images for phospho-NR2B and actin bands across all treatments, respectively. *Post hoc (Holm-Sidak) test indicates p < 0.05 versus control experiments. (B) Plotted are the mean band densities (AE SEM) for the ratio of Y1472 phospho-NR2B to NR2B expression normalized to control tissue and relative to actin (n = 6 for all conditions). (C) Above, plotted are mean band densities (AE SEM) for mBDNF protein expression normalized to control tissue and relative to actin across all conditions (n = 6 for all conditions). Below are representative images for mBDNF (14 kDa) and actin bands across all treatments, respectively. *Post hoc (Holm-Sidak) test indicates p < 0.05 versus control experiments. (D) Above, plotted are mean band densities (AE SEM) for phosphorylation of the Y706 residue of the TrkB receptor normalized to control tissue and relative to actin across different conditions (n = 3 for chronic 21 days; n = 8 for other conditions). Below are representative images for phospho-TrkB (140 kDa) and actin bands across all treatments, respectively. **Post hoc (Holm-Sidak) test indicates p < 0.05 versus all conditions. induced glutamate hypersensitivity. Chronic tolerance is characterized by a 10-fold rightward shift in the dose-response curve for EtOH inhibition of glutamate-induced phase delays compared to that seen in SCN tissue from EtOH-na€ ıve mice. This shift in sensitivity is similar to that seen previously with rapid tolerance (Lindsay et al., 2014) . Conversely, EtOH withdrawal leads to a 10-fold leftward shift in the dose-response curve for glutamate-induced phase delays. Together with our previous demonstration of acute EtOH tolerance in the SCN in vitro ), these results illustrate that the SCN circadian clock exhibits a high degree of EtOH-induced plasticity in its phase-resetting properties. Given that EtOH disrupts a variety of circadian rhythms, including hormone secretion and sleep parameters, which may increase the propensity for relapse drinking (Brower, 2003; K€ uhlwein et al., 2003) , it will be important to determine the cellular mechanisms underlying EtOH-induced plasticity in the SCN.
Prior to exploring changes at the cellular level, we sought to clarify the duration of EtOH consumption necessary to develop chronic tolerance and withdrawal-induced glutamate hypersensitivity in the SCN. Using the 4 h/d drinking paradigm, we find that mice need to consume EtOH for at least 8 days to develop chronic tolerance, consistent with other investigations (Broadwater et al., 2011) . In contrast, mice need more than 14 days of EtOH consumption to subsequently exhibit withdrawal-induced glutamate hypersensitivity. Previous research suggests that the duration of drinking necessary to induce withdrawal hypersensitivity varies across different EtOH exposure paradigms (after 4 days of vapor inhalation in Olive and Becker [2008] vs. 1 to 2 weeks of drinking in Roberto et al. [2004] and Wang et al. [2010] ). Importantly, we found that chronic EtOH drinking without withdrawal does not cause glutamate hypersensitivity. Together, the different time courses of EtOH-induced changes support the hypothesis that distinct cellular adaptations underlie their development.
Prior results indicate that under a constant no-choice EtOH drinking protocol, the SCN circadian clock does not exhibit chronic tolerance with respect to EtOH inhibition of photic phase shifts in vivo (i.e., photic phase shifts continue to be inhibited throughout the duration of EtOH consumption) in both hamsters and mice (Brager et al., 2010; Ruby et al., 2009) . Our data showing chronic tolerance assessed in vitro raise questions regarding the underlying differences. In Brager and colleagues (2010), mice consumed higher amounts of EtOH (20 g/kg/d vs. 3.36 AE 0.23 g/kg/d in the current study), and drinking was not restricted to a 4-hour period each day, while we used what is considered a "bingedrinking" like paradigm (Crabbe et al., 2017) . It should be noted, however, that relative to the total time EtOH was available in these 2 studies (24 h/d vs. 4 h/d), EtOH consumption was quite comparable. This equality is likely not that simple, however, because mice tend to maximize their EtOH consumption during early night (e.g., Brager et al., 2011) . A separate in vivo study found that 21 days of voluntary EtOH consumption induces no change in the size of photic phase shifts (suggestive of chronic tolerance), while 21 days of forced EtOH consumption leads to smaller photic phase shifts (Seggio et al., 2009) . Another study from the same laboratory (Rosenwasser et al., 2014) observed reduced effects of EtOH on circadian period after sustained high EtOH intake in rats, which is consistent with chronic tolerance, but this effect is seen in a sex-and strain-dependent fashion. Thus, the specific EtOH exposure paradigm and animal model used are critical variables to consider when investigating chronic EtOH tolerance in the SCN.
Likewise, in vivo experiments investigating EtOH withdrawal-induced changes in circadian phase shifts have shown mixed results. For instance, enhanced photic phase shifts are seen during EtOH withdrawal in hamsters (Ruby et al., 2009) , while withdrawal does not alter photic phase shifts in mice (Brager et al., 2010) . In contrast, free-running circadian periodicity after withdrawal from 12 days of EtOH exposure is altered in mice, suggesting that EtOH continues to affect clock-regulated mechanisms during withdrawal (Logan et al., 2012) . Here, we demonstrate that withdrawal-induced glutamate hypersensitivity occurs in the SCN in vitro after mice consume EtOH for 17 days but not 14 days. A careful assessment of photic phase resetting sensitivity using a range of light intensities in vivo following a 4 h/d drinking paradigm could clarify the critical variables that either lead to or prevent glutamate hypersensitivity during EtOH withdrawal.
Another important difference is that the previous studies investigated photic phase resetting in vivo versus the in vitro glutamate-induced phase resetting used here. Because EtOH affects many brain areas that directly or indirectly modulate circadian clock functioning, the lack of tolerance seen in vivo could reflect changes in EtOH actions across multiple regions that counteract or obscure changes occurring in the SCN. For example, the SCN receives serotonin (5-HT) input from the dorsal raphe nucleus that inhibits photic phase shifts (Bradbury et al., 1997) . Previously, we showed that acute application of EtOH to SCN tissue enhances serotonergic phase shifts in vitro (Prosser et al., 2008) , while EtOH inhibits serotonergic phase shifts when administered peripherally in vivo, which points to extra-SCN sites of action (Ruby et al., 2009) . Another possible explanation for the differences between in vivo and in vitro results could stem from bathapplied glutamate acting more broadly within the SCN relative to synaptically released glutamate. This possibility could be explored in future experiments using in vitro optic chiasm stimulation-induced release of glutamate in the SCN rather than bath-applied glutamate. The downside of such experiments, of course, is that it is harder to titrate the amount of glutamate released by the optic chiasm stimulation.
Hyperexcitation during EtOH withdrawal has been reported across many brain regions. This effect was described by Finn and Crabbe (1997) , who suggested that adaptations that initially develop to offset the effects of EtOH are left unopposed during withdrawal, thus leaving neurons in a hyperactive state. Withdrawal-induced hyperexcitability is thought to contribute to the synaptic remodeling observed in the orbital frontal cortex (Nimitvilai et al., 2016) . Evidence of withdrawal-induced hyperexcitation is also seen in the basolateral amygdala (BLA), as indicated by shortened paired-pulse ratio intervals and increased miniature excitatory postsynaptic current (mEPSC) amplitude and frequency (L€ ack et al., 2007) . The differences in mEPSCs seen in the BLA during chronic drinking do not persist after 24 hours of withdrawal (L€ ack et al., 2007) , consistent with our results showing differences between chronic EtOH and EtOH withdrawal conditions. Thus, withdrawal-induced glutamate hypersensitivity in the SCN is consistent with hyperexcitable states found in other brain regions.
Chronic EtOH Consumption Increases the NR2B:NR2A Ratio in the SCN To begin assessing the cellular changes underlying the EtOH-induced plasticities, we focused on NMDA receptors, which are critically involved in photic phase resetting in the SCN (Ding et al., 1997; Mintz et al., 1999; Wang et al., 2008) . We found a significant increase in the NR2B:NR2A ratio in the SCN after 21 days of drinking that is not seen with shorter durations of EtOH consumption, and this increase is maintained during EtOH withdrawal. Therefore, this change in NMDA receptor subunit expression is induced during chronic EtOH consumption but is not necessary for the expression of chronic tolerance, which is seen as early as after 10 days of drinking. However, the increase in NR2B: NR2A expression could be necessary for withdrawal-induced glutamate hypersensitivity, a possibility that will need to be explored in subsequent studies.
Although we did not see a change in total NR2B subunit expression during either chronic EtOH or withdrawal, other EtOH-induced changes could affect NMDA receptor function. For example, chronic drinking increases membrane localization of NR2B subunits in many regions (Qiang et al., 2007) . Moreover, EtOH withdrawal can increase lateral movement of NR2B containing NMDA receptors to extrasynaptic zones (Clapp et al., 2010) . Changes in receptor localization across these drinking paradigms are another possibility worth exploring.
Increased Phosphorylation of Y1472 Occurs During EtOH Withdrawal
In addition to changes in receptor subunit composition, NMDA receptor signaling is modulated by phosphorylation of specific residues. For example, phosphorylation of NR2B Y1472 potentiates NMDA receptor currents and increases synaptic recruitment of NMDA receptors (Goebel et al., 2005) . We found that during EtOH withdrawal, but not during EtOH consumption, there is a significant increase in phosphorylation of NR2B Y1472 in the SCN. Thus, this change appears to be induced by the cessation of EtOH consumption and is consistent with the glutamate hypersensitivity we observed for the SCN circadian clock. Increases in Y1472 phosphorylation have previously been seen after chronic EtOH in the rat striatum and in the rat hippocampus (Wang et al., 2010; Wu et al., 2010) . Both studies also found no change in total expression of NR2A and NR2B proteins, consistent with our findings. Moving forward, it would be interesting to assess whether pharmacological inhibition of Y1472 phosphorylation during withdrawal reduces or prevents the development glutamate hypersensitivity in the SCN.
Phosphorylation of Y1472 has been shown to increase membrane localization of NR2B-containing NMDA receptors and maintain NR2B subunit interactions with the scaffolding protein PSD-95 (Prybylowski et al., 2005; Roche et al., 2001 ). Although we did not see any changes in PSD-95 expression, others likewise have shown increased Y1472 phosphorylation during withdrawal without a change in PSD-95 expression (Clapp et al., 2010 ). Yet, there is evidence PSD-95 is involved in EtOH effects, as increased clustering of PSD-95 and its colocalization with NR2B-containing NMDA receptors occur during chronic EtOH (CarpenterHyland et al., 2004; Clapp et al., 2010) . Colocalization assays may help determine whether there are changes in PSD-95 interactions with NR2B in the SCN during EtOH withdrawal. Fig. 6 . Model depicting cellular changes associated with chronic EtOH exposure and EtOH withdrawal occurring in the SCN. After 21 days (but not 10 days) of 4 h/d chronic EtOH access, there is an increase in the ratio of NR2B to NR2A NMDA subunits. This change is not necessary for tolerance, which is seen after 10 days of chronic EtOH, so other changes must also be occurring. However, it may be a prerequisite of EtOH withdrawal-induced plasticity. During withdrawal, the increase in NR2B:NR2A ratio persists in addition to increases in Y1472 phosphorylation of NR2B subunit. Upstream, increases in mBDNF expression and Y706 phosphorylation of TrkB receptors are also seen. One possibility is that increased TrkB activity promotes NR2B phosphorylation via the Src family kinase, Fyn. These changes may be responsible for the enhanced glutamate sensitivity seen in the SCN after EtOH withdrawal.
Increases in mBDNF and TrkB Phosphorylation Occur During Withdrawal
One mechanism through which Y1472 becomes phosphorylated is via TrkB signaling. Binding of mBDNF to TrkB induces autophosphorylation of the receptor, allows activation of downstream signals, and promotes neuronal survivability. Our results show increases in mBDNF expression and TrkB phosphorylation during withdrawal. There are mixed reports in the literature regarding EtOH effects on mBDNF, including decreases in BDNF binding to TrkB in the hippocampus (Kolb et al., 2005) and increases in expression of BDNF, TrkB, and downstream kinases in the striatum (Logrip et al., 2008) . These differences suggest that the changes are region specific, with our results consistent with this conclusion. The increased TrkB phosphorylation we observe during withdrawal runs counter to results from some previous studies (Nona et al., 2013; Pandey et al., 2008) . Thus, this change may also be specific to the SCN. Nevertheless, these results are consistent with the increase in NR2B Y1472 phosphorylation we observe in the SCN following EtOH withdrawal.
Cellular Mechanisms Underlying Rapid and Chronic Tolerance in the SCN Are Still Unknown
Clearly, there is a great deal we still do not know about the cellular changes occurring in the SCN in response to EtOH, especially those associated with rapid tolerance and chronic tolerance after short durations of EtOH. It is possible that other proteins contribute to these effects. One possible candidate is a change in a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. For example, Beckley and colleagues (2016) demonstrate that AMPA receptor expression in the nucleus accumbens increases in response to a single 4-hour binge exposure to EtOH. Another likely possibility is that EtOH enhances signaling by GABA(A) receptors. Chronic EtOH exposure alters GABA subunit composition (Liang et al., 2007; Lindemeyer et al., 2014) , and we have shown that at least some effects of EtOH in the SCN involve activation of d-subunit-containing GABA(A) receptors (McElroy et al., 2009) . Given the complexity of EtOH effects in the brain, investigating both AMPA and GABA(A) receptors will likely clarify the cellular mechanisms underlying EtOH-induced plasticity in the SCN.
CONCLUSIONS
To our knowledge, these are the first data carefully delineating timing differences in the development of rapid tolerance, chronic tolerance, and EtOH withdrawal plasticity. Together with our previous studies, we have shown that multiple forms of EtOH-induced plasticity occur in the SCN in response to different EtOH exposure paradigms and that each likely involves distinct cellular mechanisms that develop over different time frames. We observed an increase in the NR2B:NR2A ratio after chronic EtOH that is still seen during EtOH withdrawal, when it additionally is accompanied by an increase in NR2B Y1472 phosphorylation, TrkB phosphorylation, and mBDNF. Some or all of these changes could be necessary for the EtOH tolerance and glutamate hypersensitivity that develop. A visual representation of these changes is shown in Fig. 6 . Because both EtOH tolerance and withdrawal can lead to increases in EtOH consumption (Bell et al., 2001; Das et al., 2016) , a better understanding of the distinct cellular processes underlying each of these conditions may improve treatments to alleviate or prevent development of alcohol dependence. The data from this study also demonstrate the power of using the SCN circadian clock to investigate nuanced differences in EtOH effects in the brain. Importantly, continuing this line of investigation should enhance our understanding of how alcohol abuse leads to disruptions in circadian rhythms and sleep.
